Johnson & Johnson Logo

Email this page: News Release

FDA Issues Complete Response Letter for XARELTO® (rivaroxaban) for the Reduction of Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome

For security reasons, registration is required before you can use this feature.
* Indicates required field